Literature DB >> 7545465

CD44 (Pgp-1) inhibits CD3 and dexamethasone-induced apoptosis.

E Ayroldi1, L Cannarile, G Migliorati, A Bartoli, I Nicoletti, C Riccardi.   

Abstract

Anti-CD3 monoclonal antibodies (MoAbs) and glucocorticoid hormones (GCH) induce apoptosis in immature thymocytes and peripheral T lymphocytes. This process is inhibited by a number of growth factors, including interleukin-2 (IL-2), IL-3, and IL-4, indicating that signals generated by membrane receptors can modulate the survival of lymphoid cells. To investigate whether signals activated by adhesion receptors have a similar activity, we analyzed the effect of CD44 (Pgp-1) adhesion molecule receptor stimulation on T-cell apoptosis induced by three stimuli (anti-CD3 MoAbs, dexamethasone [DEX] treatment, and exposure to ultraviolet irradiation [UV]) on a 3DO T-cell line. The results show that CD44 engagement, either by hyaluronic acid (HA) or anti-CD44 MoAbs, inhibits DNA fragmentation and apoptosis induced by DEX and anti-CD3 MoAbs, whereas that induced by UV, a p53-dependent phenomenon, was not inhibited. Furthermore, the antiapoptotic effect exerted through CD44 activation does not seem related to overexpression of bcl-2 or to have appreciable effects on cell proliferation. Our results indicate that adhesion molecules modulate T-cell survival by counteracting apoptosis induced by DEX or anti-CD3 MoAbs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545465

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Apoptosis: A Current Molecular Analysis.

Authors:  Dean G Tang; Arthur T Porter
Journal:  Pathol Oncol Res       Date:  1996       Impact factor: 3.201

2.  Inducible CD4+LAP+Foxp3- regulatory T cells suppress allergic inflammation.

Authors:  Wei Duan; Takanori So; Amit K Mehta; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-11-11       Impact factor: 5.422

3.  Modulation of superantigen-induced T-cell deletion by antibody anti-Pgp-1 (CD44).

Authors:  E Ayroldi; L Cannarile; C Ricardi
Journal:  Immunology       Date:  1996-02       Impact factor: 7.397

4.  Clinical significance of pAKT and CD44v6 overexpression with breast cancer.

Authors:  Pei Yu; Ling Zhou; Weifeng Ke; Ke Li
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-16       Impact factor: 4.553

5.  Induction of fibroblast apoptosis by anti-CD44 antibody: implications for the treatment of fibroproliferative lung disease.

Authors:  C Henke; P Bitterman; U Roongta; D Ingbar; V Polunovsky
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

6.  Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor.

Authors:  Y H Lin; C J Huang; J R Chao; S T Chen; S F Lee; J J Yen; H F Yang-Yen
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

7.  Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1.

Authors:  Yair Herishanu; Federica Gibellini; Ndegwa Njuguna; Inbal Hazan-Halevy; Mohammed Farooqui; Sarah Bern; Keyvan Keyvanfar; Elinor Lee; Wyndham Wilson; Adrian Wiestner
Journal:  Leuk Lymphoma       Date:  2011-06-08

Review 8.  CD44 in cancer progression: adhesion, migration and growth regulation.

Authors:  R Marhaba; M Zöller
Journal:  J Mol Histol       Date:  2004-03       Impact factor: 2.611

9.  CD44 costimulation promotes FoxP3+ regulatory T cell persistence and function via production of IL-2, IL-10, and TGF-beta.

Authors:  Paul L Bollyky; Ben A Falk; S Alice Long; Anton Preisinger; Kathy R Braun; Rebecca P Wu; Stephen P Evanko; Jane H Buckner; Thomas N Wight; Gerald T Nepom
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

10.  Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke.

Authors:  Kristian P Doyle; Tao Yang; Nikola S Lessov; Thomas M Ciesielski; Susan L Stevens; Roger P Simon; Jeffrey S King; Mary P Stenzel-Poore
Journal:  J Cereb Blood Flow Metab       Date:  2008-03-26       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.